Marie Bleakley, MD, PhD, on GVHD: Reducing Rates and Increasing Survival

2016 ASH Annual Meeting & Exposition

Marie Bleakley, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses data on using naive T-cell depletion of peripheral blood stem cells, which led to very low rates of chronic graft-vs-host-disease and high survival (Abstract 668).



Related Videos

Leukemia

Julie Vose, MD, MBA, and Anjali Advani, MD, on AML: Results of Two Trials on Vadastuximab Talirine

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Anjali Advani, MD, of the Cleveland Clinic, discuss study findings on vadastuximab talirine as ...

Hematologic Malignancies
Symptom Management

Brenda M. Sandmaier, MD, and Sagar Lonial, MD, on Preventing GVHD: Clinical Trial Results

Brenda M. Sandmaier, MD, of Fred Hutchinson Cancer Research Center, and Sagar Lonial, MD, of Emory University, discuss study findings on sirolimus combined with mycop...

Lymphoma
Geriatric Oncology

Catherine Thieblemont, MD, PhD, and Julie Vose, MD, MBA, on DLBCL: Results From the Lysa Remarc Study

Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss phase III trial find...

Leukemia

Jose F. Leis, MD, PhD, and Sagar Lonial, MD, on CLL: Ibrutinib Insights

Jose F. Leis, MD, PhD, of the Mayo Clinic, and Sagar Lonial, MD, of Emory University, discuss a session on CLL treatment (excluding transplantation): ibrutinib resist...

Hematologic Malignancies
Symptom Management

Jean M. Connors, MD, and Julie Vose, MD, MBA, on Thrombosis and Anticoagulation: Best of ASH Clinical Data

Jean M. Connors, MD, of Brigham and Women’s Hospital, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss a roundup of key findings on a cr...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.